Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project, Europe, December 2020 to May 2021Esther Kissling, Lisa Domegan, Simon de Lusignan et al.|Eurosurveillance|2021Cited by 55
Low 2018/19 vaccine effectiveness against influenza A(H3N2) among 15–64-year-olds in Europe: exploration by birth cohortEsther Kissling, Francisco Pozo, Silke Buda et al.|Eurosurveillance|2019Cited by 48
Effectiveness of complete primary vaccination against COVID-19 at primary care and community level during predominant Delta circulation in Europe: multicentre analysis, I-MOVE-COVID-19 and ECDC networks, July to August 2021Esther Kissling, Mariëtte Hooiveld, Iván Martínez‐Baz et al.|Eurosurveillance|2022Cited by 27
Effectiveness of complete primary vaccination against COVID-19 at primary care and community level during predominant Delta circulation in Europe: multicentre study analysis by age-group, vaccine brand and time since vaccination, I-MOVE-COVID-19 and ECDC networks, July–August 2021Esther Kissling, Marta Valenciano, Mariëtte Hooiveld et al.|Unknown|2021Cited by 2
Recommendations for estimating and reporting vaccine effectiveness by time since vaccination: a COVID-19 case studyEsther Kissling, on behalf of I-MOVE-COVID- and ECDC primary care study teams, Mariëtte Hooiveld et al.|American Journal of Epidemiology|2025Cited by 0